Strongbridge Biopharma (NASDAQ:SBBP)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday.
A number of other equities research analysts have also recently issued reports on SBBP. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Oppenheimer started coverage on Strongbridge Biopharma in a research note on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price target for the company. ValuEngine downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Strongbridge Biopharma has a consensus rating of “Buy” and a consensus target price of $12.25.
Shares of Strongbridge Biopharma (SBBP) remained flat at $$6.40 during trading on Wednesday. 135,956 shares of the stock traded hands, compared to its average volume of 147,115. Strongbridge Biopharma has a twelve month low of $2.00 and a twelve month high of $8.85. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61.
A number of hedge funds have recently bought and sold shares of SBBP. State of Wisconsin Investment Board acquired a new position in Strongbridge Biopharma in the second quarter valued at about $114,000. Rhumbline Advisers acquired a new position in Strongbridge Biopharma in the second quarter valued at about $154,000. California State Teachers Retirement System acquired a new position in Strongbridge Biopharma in the second quarter valued at about $277,000. Teachers Advisors LLC acquired a new position in Strongbridge Biopharma in the second quarter valued at about $297,000. Finally, Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma in the second quarter valued at about $331,000. 57.53% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/09/strongbridge-biopharma-sbbp-rating-reiterated-by-cantor-fitzgerald.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.